AR-14034 SR implant lower dose

Phase 2

Alcon Research (ALC)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Apr '27

ALCPhase 2$11.6B

AR-14034 SR implant lower dose Phase 2 Est. Readout

AR-14034 SR implant lower dose• Neovascular Age-related Macular Degeneration (nAMD)139

Apr 2027~Confirmed

CT.gov

00%

Competitive Landscape

2 competitors in Neovascular Age-related Macular Degeneration (nAMD)

RHHBYVabysmo

RHHBYranibizumab injection

Approved

View Full Landscape

Drug Information

Target Indication

Neovascular Age-related Macular Degeneration (nAMD)

Clinical Trial

NCT05769153

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ALC

Alcon Research

Ophthalmic Goods•Europe•NASDAQ

Related Pipeline

Ofloxacin otic solutionPhase 3

Acute Otitis Media

Difluprednate 0.05% ophthalmic emulsionPhase 3

Endogenous Anterior Uveitis

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%Phase 3

Allergic Conjunctivitis

AL-4943A ophthalmic solutionPhase 3

Allergic Conjunctivitis

Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solutionPhase 3

Glaucoma, Open-angle

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts